A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of the Efficacy, Safety, and Tolerability of a Single Oral Administration of CP101 for the Prevention of Recurrent Clostridioides difficile Infection (PRISM4)

Phase 3 trial will evaluate the efficacy of CP101 treatment relative to placebo in adults with previously treated recurrent Clostridioides difficile infection (CDI) and evaluate the safety and tolerability of CP101 treatment compared to placebo in adults with previously treated recurrent CDI.

0